Overview

The only approved drug that acts on sexual desire centrally rather than on blood flow peripherally. Approved for a specific indication in a specific population, and used far outside it — including in men, where it has never been approved.

FDA ApprovedFDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women

At a glance

Regulatory status	FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women
Drug class	Melanocortin receptor agonist (MC3R/MC4R) — cyclic heptapeptide
Route	Subcutaneous autoinjector, as needed
Half-life	~2.7 hours
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	RECONNECT phase 3 trials in premenopausal women with HSDD; earlier studies in erectile dysfunction including an intranasal formulation that was discontinued over blood-pressure effects.

How it works

Activates melanocortin receptors in the hypothalamus, modulating dopaminergic pathways involved in sexual desire and arousal. Unlike PDE5 inhibitors, it acts on central desire circuits rather than on penile or genital vascular smooth muscle.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

Two adequately powered phase 3 trials with validated patient-reported endpoints.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Statistically significant desire improvement Strong evidence

Phase 3 trials showed improvement in validated desire and distress scores versus placebo, sufficient for FDA approval.
On-demand rather than daily dosing Strong evidence

Taken ahead of anticipated activity, unlike flibanserin which requires continuous daily use.
Central mechanism Strong evidence

Addresses desire directly, useful where vascular-acting drugs are irrelevant to the problem.
No alcohol interaction restriction Moderate evidence

A practical advantage over flibanserin, which carries alcohol warnings.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Nausea Moderate evidence

The dominant adverse effect — roughly 40% of patients in trials, and about 1 in 8 required an antiemetic.
Transient blood pressure increase Serious

Systolic rises of several mmHg with a compensatory heart-rate decrease. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
Hyperpigmentation with repeated dosing Moderate evidence

Focal darkening of the face, gums and breasts occurred in trials, more often with frequent use; may be permanent. Dosing is capped at 8 doses per month partly for this reason.
Modest average effect size Moderate evidence

Statistically significant but clinically modest; response rates leave many patients unimproved.
Flushing and injection-site reactions Minor

Common but generally mild.
Widespread off-label and grey-market use Serious

Heavily sold as unapproved "research PT-141" for men and postmenopausal women — populations where efficacy and safety were not established.

Who should avoid it

Uncontrolled hypertension
Known cardiovascular disease
Pregnancy
Postmenopausal women and men (outside approved indication)

If used under medical supervision, monitor

Blood pressure before initiation and periodically
Skin and gum pigmentation
Dose frequency — no more than one dose in 24 hours, 8 per month

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Antihypertensives — bremelanotide transiently raises blood pressure and can offset them
Naltrexone — reduced exposure; concurrent use is not recommended
Oral drugs with slow absorption — bremelanotide slows gastric emptying
Alcohol — compounds nausea

Regulatory & legal status

Prescription drug for its labelled indication. "Research grade" PT-141 sold online is unapproved.

Infographic

PT-141 (Bremelanotide) — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

libidoHSDDmelanocortinapprovedsexual health

Related peptides in Sexual Health & Melanocortin

Terms used on this page

Sexual Desire vs Arousal: Sexual desire is the motivational interest in sexual activity while arousal is the genital and subjective response to stimulation, and the two dissociate enough that trials measure them separately.
Dopaminergic Signalling: Dopaminergic signalling is neurotransmission by dopamine across anatomically separate pathways controlling movement, reward learning, executive function and prolactin release.
Melanocortin System: The melanocortin system is the POMC-derived signalling network in which alpha-MSH and ACTH act on five receptors to control pigmentation, adrenal steroid output, appetite and energy balance.
Sample Size and Power Calculation: Statistical power is the probability that a trial detects a real effect of a specified size, and the sample size calculation is the arithmetic that fixes how many participants that requires.
Phase 3 Trial: A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.
Placebo and Placebo Control: A placebo is an inactive intervention matched to the real one in appearance and route, used as a control arm so that improvement caused by the drug can be separated from improvement that would occur anyway.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.